WithdrawnNot Applicable

Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE

Stopped: Study withdrawn by clinical team

0Started 2023-05-11

Plain-language summary

MICROPULSE study aims to evaluate the efficacy of navigated microsecond laser (nMSL) for chronic central serous chorioretinopathy (CSCR).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years and older * vision complaints for more than 6 weeks * subretinal fluid confirmed on OCT * diagnosis of CSCR confirmed by fluorescein and indocyanine green angiography * Signed informed consent * Affiliated or beneficiary of health insurance Exclusion Criteria: * History of treatment of CSC with other modalities (PDT, eplerenone) in the past 3 months * Other macular conditions : Age-related Macular Degeneration (AMD), polypoidal vasculopathy, choroidal neovascularization * Cataract or opacities interfering with acquisition or treatment * Myopia\> 6 diopter * Visual acuity\<20/200 * Treatment with steroids (per-os, inhaled or cutaneous) in the past 3 months * Intra-vitreal injections of anti-VEGF (Vascular Endothelial Growth Factor) or steroids in the past 3 months * History of allergy to fluorescein or indocyanine * Inability to agree to participate to the study * Pregnant or breastfeeding woman * Patient under legal protection

What they're measuring

central macular thickness

Timeframe: Month 3

Trial details

NCT IDNCT05679180

SponsorUniversity Hospital, Bordeaux

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-05-24

View on ClinicalTrials.gov More Central Serous Chorioretinopathy trials